Drug intelligence / Profile preview

ATB-1013

Development stage: Phase 1
Lead developer: Autotelic Bio
Administration: Oral

Overview

ATB-1013 is an investigational oral tablet developed by Autotelicbio. It is currently being evaluated in a Phase 3 clinical trial for the treatment of essential hypertension and type II diabetes mellitus. The specific mechanism of action for ATB-1013 is not disclosed in the provided context.

Beyond the preview

Go deeper on ATB-1013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATB-1013.

Explore the full profile